Why did City Therapeutics' $200 million IPO matter for extrahepatic RNAi?

City Therapeutics’ $200 million IPO mattered because investors backed an RNAi company with near-term clinical programs and a platform aimed at delivering treatments beyond the liver. The financing suggested public markets may still support modality stories that combine pipeline assets with the harder, longer-term promise of extrahepatic RNAi delivery.